A two-dose series of Takeda’s dengue fever vaccine candidate, TAK-003, has demonstrated strong protective effects in the company’s long-term phase 3 TIDES study in more than 20,000 healthy children and adolescents.

Over the four-and-a-half-year study, the vaccine demonstrated 84.1 percent efficacy against hospitalization and 61.2 percent vaccine efficacy against infection with dengue, with better results for seropositive than for seronegative individuals.

The vaccine is currently under regulatory review in the EU and in several dengue-endemic countries and the TIDES trial is now evaluating the safety and efficacy of a booster dose.